Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,002
datasets available to search
ShareScore release 0.9.0
Dataset results
2,002 results for “sarcoma”
DNA methylation in sarcoma patients
GEO Series GSE172468. Homo sapiens. 35 samples. Type: Methylation profiling by genome tiling array.
Modeling the initiation of Ewing sarcoma tumorigenesis in human Embryonic Stem Cells
GEO Series GSE141889. Homo sapiens. 16 samples. Type: Expression profiling by array; Expression profiling by high throughput sequencing.
Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma
DNA and RNA were isolated from snap frozen primary tumor tissue (human and mouse), and DNA was isolated from matched normal tissue (region matched non-tumor tissue for human, tail section for mouse). A mouse leg was also injected with cardiotoxin to induce tissue damage was taken following sacrifice and was snap frozen, then processed for RNA isolation to serve as a mouse tissue-normal for RNA sequencing. All sequencing was performed at the OHSU MPSSR core.
Mouse Models of Alveolar/Embryonal Rhabdomyosarcoma & Spindle Cell Sarcomas
A series of conditional mouse models of embryonal rhabdomyosarcoma, alveolar rhabdomyosarcoma and spindle cell sarcoma were generated and validated for relavence to corresponding human cancers.
Pediatric Sarcoma: Rhabdomyosarcoma & Ewing's Sarcoma
Using Affymetrix oligonucleotide microarrays, we analyzed mRNA gene expression patterns of 12 primary pediatric rhabdomyosarcomas (RMS) and 11 Ewing's sarcomas (EWS), which belong to the small round blue cell tumors (SRBCTs). Diagnostic classification of these cancers is frequently complicated by the highly similar appearance in routine histology, and additional molecular markers could significantly improve tumor classification. A combination of three independent statistical approaches (t-test, SAM, k-nearest neighborhood analysis) resulted in 101 highly significant probe sets that clearly discriminate between EWS and RMS. We identified novel marker transcripts that have not been previously associated with either RMS or EWS yet, including CITED2, glypican 3 (GPC3), and cyclin D1 (CCND1). Expression levels for selected candidate genes were validated by quantitative real-time reverse-transcription PCR. Furthermore, to identify biologically meaningful trends, functional annotations were assigned to 946 genes differentially expressed between EWS and RMS (t-test). Genes involved in protein biosynthesis (n = 28) and complex assembly (n = 9), lipid metabolism (n = 23), energy generation (n = 22), and mRNA processing (n = 11) were expressed significantly higher in EWS. Thus, functional annotation of tumor-specific genes reveals detailed insights into tumor biology and differentiation-specific expression patterns and gives important clues related to the possible cellular origin of these pediatric tumors.
Profiling the transcriptional heterogeneity of diverse pediatric solid tumors - Non-rhabdomyosarcoma soft tissue sarcomas
For more information, including a more complete description, data generator contact information, and reference, please see: https://scpca.alexslemonade.org/projects/SCPCP000013.
Profiling the transcriptional heterogeneity of diverse pediatric solid tumors - Ewing sarcoma
For more information, including a more complete description, data generator contact information, and reference, please see: https://scpca.alexslemonade.org/projects/SCPCP000015.
Single-cell Atlas of Pediatric Sarcoma
For more information, including a more complete description, data generator contact information, and reference, please see: https://scpca.alexslemonade.org/projects/SCPCP000017.
TARGET: Kidney, Clear Cell Sarcoma of the Kidney (CCSK)
To further explore some more aggressive subtypes in pediatric cancer already under study in OCG, CGCI is partnering with TARGET initiative to support extensive sequencing analysis of three hard to treat childhood cancers: refractory to treatment cases of acute myeloid leukemia and two rare kidney tumors; clear cell sarcoma of the kidney (CCSK) and rhabdoid tumor. CCSK is a rare, aggressive kidney tumor that usually occurs in children younger than 3 years of age and little is known about the biology of this disease. There are 13 patient cases in the CCSK dataset, each with gene expression, methylation and comprehensive next-generation sequencing to include whole genome sequencing of tumor/normal pairs and mRNA-seq.
Pediatric In Vivo Testing Program –Sarcoma, Kidney, and Liver Cancers
Cancer in children is rare with approximately 15,700 new cases diagnosed annually in children 21 years or younger in the U.S. Through use of multimodality therapy (surgery, radiation therapy, and aggressive chemotherapy), 70% of patients will be `cured' of their disease, and 5-year Event-Free Survival (EFS) exceeds 80%. Consequently, the number of patients that can be enrolled in phase I/II clinical trials is small, and most patients will have been extensively treated, hence drug/radiation resistant. Thus, preclinical studies that accurately translate into effective clinical therapy are an essential component of pediatric drug development.
Pediatric In Vivo Testing Program – Sarcomas and other Solid Tumors
We established a preclinical testing program that has created >300 genomically-characterized pediatric solid tumor patient- derived xenograft (PDX) models between the pediatric oncology programs at Memorial Sloan Kettering Cancer Center and University of California San Francisco. We propose to leverage this large portfolio of models across a diversity of diseases, along with the deep expertise of the team, to establish a NCI Pediatric In Vivo Testing Program (Ped-In Vivo-TP) Research Team focused on pediatric bone and soft tissue sarcomas, renal tumors, desmoplastic small round cell tumor (DSRCT) and other rare pediatric solid tumors.
Gabriella Miller Kids First (GMKF) Pediatric Research Program in Susceptibility to Ewing Sarcoma Based on Germline Risk and Familial History of Cancer
Open the record for dataset details and reuse information.
Pediatric In Vivo Testing Program –Sarcoma, Kidney, and Liver Cancers
Open the record for dataset details and reuse information.
Pediatric In Vivo Testing Program – Sarcomas and other Solid Tumors
Open the record for dataset details and reuse information.
Transcriptional constraint of EWS/FLI by an ETS transcription factor promotes Ewing sarcoma growth [CUT&RUN]
GEO Series GSE211852. Homo sapiens. 6 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Dataset related to article "Adjuvant volumetric modulated arc therapy compared to 3D conformal radiation therapy for newly diagnosed soft tissue sarcoma of the extremities: outcome and toxicity evaluation."
<p>OBJECTIVE:</p> <p>To assess the impact of adjuvant volumetric modulated arc therapy (VMAT) compared with three-dimensional conformal radiation therapy (3DCRT) in terms of toxicity and local control (LC) in patients with soft tissue sarcoma of the extremities.</p> <p>METHODS:</p> <p>From 2004 to 2016, 109 patients were treated, initially using 3DCRT and subsequently with VMAT. Clinical outcome was evaluated by contrast-enhanced MRI, thoracic and abdominal CT 3 months after treatments and then every 6 months. Toxicity was evaluated with Common Terminology Criteria for Adverse Events scale v. 4.3.</p> <p>RESULTS:</p> <p>Patients presented Stage III soft tissue sarcoma disease (77%), localized tumor (95%) at the lower extremity (87%), adipocytic histotype (46%). Surgical resection was performed in all patients, followed by adjuvant 3DCRT in 38, and VMAT in 71. The median total dose was 66 Gy/33 fractions (range 60-70 Gy;25-35 fractions). More successful bone sparing was recorded using VMAT (<em>p</em> < 0.001). Median follow-up was 61 months, 93 and 58 months for 3DCRT and VMAT group, respectively. The 2- and 5 year LC were 95.3±2.1%, and 87.4±3.4% for the whole cohort, 92.0±4.5%, 82.9±6.4% for 3DCRT, 97.1±2.0%, 89.6±4.1% for VMAT (<em>p</em> = 0.150). On univariate and multivariate analysis the factors recorded as conditioning LC were the status of the surgical resection margins (<em>p</em> = 0.028) and the total dose delivered (<em>p</em> = 0.013).</p> <p>CONCLUSION:</p> <p>The availability of modern radiotherapy technique permit a better conformity on the target with maximum sparing of normal tissue and acceptable side-effects. VMAT is a safe and feasible treatment with limited rate of toxicity, compared to 3DCRT. Results on LC of VMAT are encouraging.</p> <p>ADVANCES IN KNOWLEDGE:</p> <p>Soft tissue sarcoma of the extremities can benefit from the use of VMAT, with a reduction of the high dose to bones to avoid radiation osteonecrosis. An adequate total dose of at least 66 Gy and a radical surgical margin allow a good local control.</p>
RNAseq dataset of myeloid sarcoma samples
<p>RNAseq dataset of 10 myeloid sarcoma samples </p>
Direct Costs of Care for Adults with Soft Tissue Sarcomas: A Population-Based Study
<p>The clinical treatment of soft tissue sarcoma (STS) has evolved substantially over the last decade. This population-based cohort study based on real-world data included all incidental STS recorded by the Veneto Cancer Registry in 2017. Data on hospital admissions, emergency department and outpatient visits, drug prescriptions, and use of medical devices within two years from STS diagnosis were obtained from administrative databases. The average per-patient real-world costs over this two-year period, in total and by single expenditure item, were calculated and stratified by stage of disease at diagnosis, tumor histology and tumor site. The mean total cost per patient amounted to EUR 16,793. A higher TNM stage at diagnosis was associated with higher healthcare costs, as follows: compared with stage I, the average total cost per patient was 1.32, 2.18 and 3.36 times greater for stages II, III and IV, respectively. Hospital stays generated the greatest costs (averaging EUR 7950 per patient), followed by outpatient visits (mean EUR 3947 per patient) and drug prescriptions (mean EUR 3664 per patient). Given the paucity of population-based studies, the present results can serve as a reference for further cost-effectiveness analyses on care strategies for patients with STS.</p>
Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020)
ClinicalTrials.gov study NCT03493165. IPD Sharing: Not stated. Countries: 0. Publications: 0.
In Vitro and In Vivo Characterization of a Preclinical Radiation-Adapted Model for Ewing Sarcoma
GEO Series GSE98712. Homo sapiens. 6 samples. Type: Expression profiling by array.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.